Lung Clinical Trials

With multiple research labs at Cedars-Sinai, our leading lung specialists and research scientists work together to pioneer new imaging technologies, therapies and minimally invasive surgical techniques. As a patient with us, you'll have the potential to participate in groundbreaking pulmonary clinical trials.

Questions? See the Clinical Trial FAQs.


Click below to view clinical trials by areas:

COVID-19

Condition: COVID-19

Participant Requirements:

  • Currently not hospitalized
  • Has one or more mild or moderate COVID-19 symptoms
  • Must have sample collection for first positive SARS-CoV-2 viral infection determination ≤3 days prior to beginning the study treatment

Summary:

The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called LY3819253, alone and in combination with the drug LY3832479, in individuals with mild to moderate COVID-19. 

Condition: COVID-19

Participant Requirements:

  • 18-65 years old
  • Currently not hospitalized
  • Has one or more mild or moderate COVID-19 symptoms

Summary:

The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called LY3819253, alone and in combination with the drug LY3832479, in individuals with mild to moderate COVID-19. Mobile health visits will be offered to provide the required study assessments. 

Interstitial Lung Disease

Condition: Idiopathic pulmonary fibrosis

Participant Requirements:

  • ≥40 years old
  • Diagnosed with IPF within four years of screening
  • Diagnosis of IPF is supported by HRCT and historical surgical lung biopsy

Summary:

The purpose of this study is to determine the effects of an investigational drug called CC-90001 on patients diagnosed with idiopathic pulmonary fibrosis (IPF), a condition in which scarring of the lungs occurs.

Condition: Idiopathic pulmonary fibrosis

Participant Requirements:

  • Between 40 and 80 years old
  • Diagnosis of idiopathic pulmonary fibrosis (IPF) within 5 years

Summary:

This study focuses on individuals who have idiopathic pulmonary fibrosis (IPF) and are between 40 and 80 years old. The purpose of the study is to evaluate the safety of an experimental medication called ND‑L02‑s0201 when administered at two dose levels compared with placebo (inactive substance).

ND-L02-s0201 is made up of tiny particles of fat that also contain a small amount of RNA (ribonucleic acid) that is the active drug. The RNA in ND-L02-s0201 is designed to block the lungs from making a protein called "heat shock protein 47" (HSP47) for a limited period of time. It is thought that blocking the lungs from making HSP47 will help treat IPF because one of the roles of HSP47 is to help make collagen, which is involved in fibrosis (scarring).

Participation in the study will be approximately 40 weeks, including a screening and baseline period of up to 6 weeks, a treatment period of 24 weeks and a follow-up period of 10 weeks. Participants will attend 16-17 on-site visits at Cedars-Sinai and will receive an IV study drug infusion every 2 weeks at Cedars-Sinai during the treatment period.

Condition: Idiopathic pulmonary fibrosis

Participant Requirements:

  • Between 40 and 80 years old
  • Women of childbearing potential and all male participants must agree to use contraception
  • Features consistent with idiopathic pulmonary fibrosis (IPF) within 5 years prior to screening

Summary:

The purpose of this study is to evaluate the safety and tolerability of an experimental drug called TRK-250 after single and multiple inhaled doses in patients with idiopathic pulmonary fibrosis (IPF). TRK-250 is intended to inhibit the messages in the cell that create a protein involved in lung fibrosis (scarring). This study will be conducted in two parts, single inhaled dose (Part A) and multiple inhaled doses (Part B). Subjects in both parts will be randomly assigned to receive either TRK-250 or placebo (inactive substance). 

Condition: Idiopathic pulmonary fibrosis

Participant Requirements:

  • At least 40 years old
  • Diagnosis of idiopathic pulmonary fibrosis (IPF) for up to 5 years before screening
  • FVC (pulmonary function test) percent of predicted ≥45%; historical FVC for entry in the study is permitted if within 1 month of screening

Summary:

This study focuses on individuals who have been diagnosed with idiopathic pulmonary fibrosis (IPF), a condition in which the air sacs in the lungs become damaged and lead to build-up of scar tissue (called fibrosis). The purpose of the study is to determine the safety and tolerability of an investigational drug called PLN-74809 compared to a placebo (inactive substance).

Lung Cancer

Lung Nodules

Condition: Lung nodules

Participant Requirements:

  • At least 18 years old
  • No prior history of any cancer
  • Willing and able to donate up to 50 mL of blood via venipuncture

Summary:

The purpose of this study is to develop blood tests that will provide information for individuals who have nodules (growths) in their lungs. The study will collect blood samples from people with lung nodules in order to develop the blood tests.

Pulmonary Vascular Disease

Condition: Idiopathic, heritable, connective tissue disease-associated and HIV-associated pulmonary arterial hypertension

Participant Requirements:

  • Confirmed clinical diagnosis of IPAH, HPAH, PAH-CTD, PAH-HIV
  • NYHA Functional Class: II or III
  • 18-75 years old

Summary:

This study focuses on patients with pulmonary arterial hypertension (PAH) from the following subgroups: idiopathic PAH (IPAH), heritable PAH (HPAH), PAH associated with connective tissue disease (PAH-CTD) and PAH associated with HIV (PAH-HIV). The study is designed to evaluate the investigational use of a biologic product called CAP-1002. CAP-1002 consists largely of heart stem cells ("CDCs") grown from donated tissue from human heart muscle. The purpose of the study is to determine the maximum feasible dose and safety of CAP-1002 administered by central intravenous infusion (IV line) in PAH patients belonging to one of the subgroups listed above who have been started on PAH-specific medications. CAP-1002 will be used in addition to the participant’s regular treatment regimen.

Condition: Pulmonary hypertension, chronic obstructive pulmonary disease

Participant Requirements:

  • At least 18 years old
  • Diagnosis of pulmonary hypertension due to chronic obstructive pulmonary disease (PH-COPD); clinical diagnosis of COPD
  • Willing to undergo right heart catheterization during first screening visit if a prior right heart catheterization has not been performed within the past 12 months

Summary:

This study focuses on individuals who have pulmonary hypertension (PH) due to chronic obstructive pulmonary disease (COPD) [PH-COPD] and thus have high blood pressure in their lungs. The purpose of the study is to evaluate the safety and effectiveness of inhaled treprostinil in improving exercise ability in patients with PH-COPD when compared to an inactive solution (placebo).

Condition: Pulmonary hypertension

Participant Requirements:

  • At least 18 years old
  • Females must not be pregnant or lactating; males and females must use contraception
  • Confirmed diagnosis of World Health Organization (WHO) Group 3 pulmonary hypertension

Summary:

The purpose of this study is to evaluate the safety of a drug called treprostinil (Tyvaso) and the effectiveness of inhaled treprostinil in patients with pulmonary hypertension (PH) associated with interstitial lung disease (ILD) or combined pulmonary fibrosis and emphysema (CPFE). Researchers will examine the participant's ability to exercise after taking treprostinil.

Condition: Heart failure, pulmonary vascular disease

Participant Requirements:

  • At least 18 years old
  • Signs or symptoms of heart failure requiring treatment with at least one oral diuretic
  • Left ventricular ejection fraction (LVEF) ≥40%

Summary:

While several drugs are available to manage heart failure symptoms, no treatment has been approved specifically for left heart failure with preserved ejection fraction and pulmonary vascular disease. The purpose of the study is to determine the safety and effectiveness of a drug called macitentan in patients with this condition.

Condition: Pulmonary hypertension, heart failure

Participant Requirements:

  • 18–85 years old
  • Has undergone a right heart catheterization within 180 days of baseline assessment
  • Diagnosis of heart failure with a left ventricular ejection fraction ≥45%

Summary:

This study focuses on individuals who have pulmonary hypertension (PH) associated with left-sided heart failure with preserved ejection fraction (HFpEF). PH associated with HFpEF causes high blood pressure in the lungs due to the heart’s inability to function properly. The purpose of the study is to evaluate how oral treprostinil works to treat this condition. Researchers will examine the effect of oral treprostinil on the participant’s ability to exercise, as well as the time that PH associated with HFpEF remains stable, improves, or worsens.

Sepsis

Condition: Sepsis-induced hypotension

Participant Requirements:

  • At least 18 years old
  • Has a suspected or confirmed infection
  • Sepsis-induced hypotension defined as systolic blood pressure <100 mmHg or mean arterial pressure (MAP) <65 mmHg, or receiving a vasopressor infusion after a minimum of at least 1 liter of fluid

Summary:

This study focuses on individuals diagnosed with low blood pressure due to sepsis (a serious infection) and whose blood pressure has stayed low after receiving fluid. The purpose of the study is to evaluate methods of using intravenous fluids (fluids given through a small tube placed in the vein) and vasopressors (medicines used to raise blood pressure) in the treatment of sepsis.